

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: HANSEN et al.	Docket No: 366929-018US (396515)
Serial No.: 10/776,934	Confirmation No.: 2105
Filed: February 10, 2004	Group Art Unit: 1635
For: OLIGOMERIC COMPOUNDS FOR THE MODULATION SURVIVIN EXPRESSION	Examiner: CHONG, Kimberly

COMBINED REVOCATION AND POWER OF ATTORNEY AND STATEMENTS
UNDER 37 CFR §§ 3.73(B) & 3.71 AND REQUEST FOR CHANGE OF
ATTORNEY DOCKET NUMBER

ENZON PHARMACEUTICALS, INC., a Delaware corporation, states that it is:

- ☐ the assignee of the entire right, title and interest; *or*
- ☒ an assignee of 50% of the entire right, title and interest

in the above-captioned patent application by virtue of either:

A. ☐ an assignment from the inventor(s) of the above-captioned application ☐ recorded in the United States Patent and Trademark Office at Reel _____, Frame ____, or ☐ for which a true copy thereof is attached hereto; *or*

B. ☒ a chain of title from the inventor(s) of the above-captioned application to ENZON PHARMACEUTICALS, INC. as shown below:

1. From the inventor(s) to SANTARIS PHARMA A/S of 100% interest, recorded in the United States Patent and Trademark Office at Reel 015565, Frame 0265, or ☐ for which a true copy thereof is attached hereto; and

2. From SANTARIS PHARMA A/S to ENZON PHARMACEUTICALS, INC. of 50% interest, recorded in the United States Patent and Trademark Office at Reel 019589, Frame 0029, or ☐ for which a true copy thereof is attached hereto.

☒ As required by 37 CFR § 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to ENZON PHARMACEUTICALS, INC. was, or concurrently is being, submitted for recordation pursuant to 37 CFR § 3.11.

☒ The undersigned hereby authorizes insertion of the recordation information, including Reel and Frame No., when it becomes available, after the document has been executed.

ENZON PHARMACEUTICALS, INC., hereby revokes all previous powers of attorney and hereby appoints **Daniel M. Becker**, Registration No. 38,376, and the **Dechert LLP** attorneys and agents associated with **Customer Number 37509** as its attorneys with full power of substitution and revocation, to prosecute the above-captioned application and to transact all business in the U.S.P.T.O. connected therewith, including full power of association, substitution, and revocation, said appointment being to the exclusion of the inventor(s) and his/her attorney(s) in accordance with the provisions of 37 CFR § 3.71; provided that if any one of the attorneys presently associated with Customer Number 37509 ceases to be affiliated with the law firm of Dechert LLP as partner, employee or counsel, such attorney's appointment as attorney and all powers derived therefrom shall terminate on the date such attorney ceases being so affiliated.

Please direct all correspondence in the captioned application to:

Customer No. 37509
Dechert LLP
P.O. Box 390460
Mountain View, CA 94039-0460
Tel: (650) 813-4800
Fax: (650) 813-4848

The attorney docket number for this application was formerly entered as 58610 (71432). It has since been changed to docket number 366929-018US (396515). Please use this new docket number in reference to this application for all future communications.

The undersigned, whose title is supplied below, is authorized to act on behalf of the assignee.

Date:	<u>Feb. 28, 2008</u>	Assignee:	<u>ENZON PHARMACEUTICALS, INC.</u>
		Signed:	<u>Margaret Albanese</u>
		Print Name:	<u>Margaret Albanese</u>
		Print Title:	<u>Director, Intellectual Property</u>